BridgeBio Pharma, Inc. (BBIO) — insider trading
Health Care · Nasdaq
BridgeBio Pharma, Inc. (BBIO) has 41 reported SEC Form 4 insider transactions in our data, including 7 open-market sales among the most recent 41 (latest 2026-07-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-09 | Cook Jennifer E. | Director | Option exercise / conversion (derivative) | 17,167 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | Director | Option exercise / conversion (derivative) | 112,422 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | Director | Option exercise / conversion (derivative) | 19,000 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | Director | Open-market sale | 112,422 | $90.00 | $10.12M | Form 4 |
| 2026-07-09 | Cook Jennifer E. | Director | Open-market sale | 36,167 | $84.00 | $3.04M | Form 4 |
| 2026-07-09 | Cook Jennifer E. | Director | Option exercise / conversion | 17,167 | $16.75 | $287.5K | Form 4 |
| 2026-07-09 | Cook Jennifer E. | Director | Option exercise / conversion | 112,422 | $29.00 | $3.26M | Form 4 |
| 2026-07-09 | Cook Jennifer E. | Director | Option exercise / conversion | 19,000 | $8.45 | $160.6K | Form 4 |
| 2026-07-09 | Ellis Andrea | Director | Option exercise / conversion (derivative) | 17,167 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Ellis Andrea | Director | Open-market sale | 17,167 | $84.00 | $1.44M | Form 4 |
| 2026-07-09 | Ellis Andrea | Director | Option exercise / conversion | 17,167 | $16.75 | $287.5K | Form 4 |
| 2026-06-24 | Cook Jennifer E. | Director | Option exercise / conversion (derivative) | 17,167 | $0.00 | $0 | Form 4 |
| 2026-06-24 | Cook Jennifer E. | Director | Option exercise / conversion (derivative) | 20,000 | $0.00 | $0 | Form 4 |
| 2026-06-24 | Cook Jennifer E. | Director | Open-market sale | 37,167 | $70.00 | $2.60M | Form 4 |
| 2026-06-24 | Cook Jennifer E. | Director | Option exercise / conversion | 17,167 | $16.75 | $287.5K | Form 4 |
| 2026-06-24 | Cook Jennifer E. | Director | Option exercise / conversion | 20,000 | $8.45 | $169.0K | Form 4 |
| 2026-06-23 | Valantine Hannah | Director | Open-market sale | 2,196 | $68.57 | $150.6K | Form 4 |
| 2026-06-23 | Cook Jennifer E. | Director | Open-market sale | 2,196 | $68.57 | $150.6K | Form 4 |
| 2026-06-22 | MCCORMICK FRANK | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | MCCORMICK FRANK | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | MOMTAZEE JAMES C | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | MOMTAZEE JAMES C | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Hassan Fred | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Hassan Fred | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Ellis Andrea | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Ellis Andrea | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | DANIELS RONALD J | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | DANIELS RONALD J | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | AGUIAR ERIC | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | AGUIAR ERIC | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | HOMCY CHARLES J | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | HOMCY CHARLES J | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Lo Andrew | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Lo Andrew | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Valantine Hannah | Director | Option exercise / conversion (derivative) | 2,808 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Valantine Hannah | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Valantine Hannah | Director | Open-market sale | 2,808 | $68.00 | $190.9K | Form 4 |
| 2026-06-22 | Valantine Hannah | Director | Option exercise / conversion | 2,808 | $41.73 | $117.2K | Form 4 |
| 2026-06-22 | Valantine Hannah | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Cook Jennifer E. | Director | Grant / award / vesting (derivative) | 5,277 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Cook Jennifer E. | Director | Grant / award / vesting | 3,990 | $0.00 | $0 | Form 4 |
Ask the chat about BBIO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BridgeBio Pharma, Inc. (BBIO).
Last updated 2026-07-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.